- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00271635
Ascorbic Acid Treatment in CMT1A Trial (AATIC) (AATIC)
Phase 2 Study of Ascorbic Acid Treatment in Charcot-Marie-Tooth Type 1A
Study Overview
Status
Intervention / Treatment
Detailed Description
Charcot-Marie-Tooth type 1A (CMT1A), or hereditary motor and sensory neuropathy type Ia (HMSN Ia), is an autosomal dominant disease, most often caused by a 1.5 Mb duplication of chromosome 17, giving rise to three copies of the peripheral myelin protein 22 gene (PMP22). Mutations in this gene rarely cause CMT1A. It is a primarily demyelinating neuropathy, as has been shown in nerve conduction studies and in histopathological investigations. The conduction velocities of peripheral nerves are already slowed at the age of five years. Longitudinal data show that these conduction velocities do not change during life, indicating that the degree of demyelination is rather constant during life.
CMT1A is characterized clinically by distal muscle weakness and wasting, legs more than arms, impaired distal sensation, and reduced or absent reflexes. Moreover, foot and hand deformities are often encountered. In childhood, disease progression has been shown. In adults, there are indications for disease progression, but properly conducted longitudinal studies are awaited. Cross-sectional studies show that disease severity in adults is variable: a group of CMT1A patients is asymptomatic (5-10%), whereas other patients are wheelchair dependent (5-10%), still most have the classical CMT phenotype. Therapy is symptomatic and aims at maintaining functional possibilities and learning compensation mechanisms. There is no medication available that stabilizes or improves the clinical signs and symptoms.
Ascorbic acid is needed in in vitro studies for proper myelination of axons (in cultures containing serum). Recently, in a mouse model for CMT1A it has been shown that ascorbic acid improves the CMT1A phenotype. Mice (2-4 months old) treated with ascorbic acid once a week during three months showed an increase in the percentage of myelinating nerve fibers and showed better results in locomotor tests.
In this phase 2 study we will study the efficacy and safety of ascorbic acid in young patients with CMT1A. We will investigate whether ascorbic acid induces remyelination by measuring the nerve conduction of a peripheral nerve during a one year study period. CMT1A patients aged 12 years or older may cooperate sufficiently in nerve conduction studies. We include young patients, as clinical signs and symptoms especially develop relatively early in life. These signs and symptoms are due to axonal dysfunction, secondary to the demyelination. This is why we will investigate additionally whether there is an effect of ascorbic acid treatment on axonal function, strength and disabilities.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
P.O.Box 22660
-
Amsterdam, P.O.Box 22660, Netherlands, 1100 DD
- Department of Neurology Academic Medical Center University of Amsterdam
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- DNA-proven CMT1A patients
- Age 12-25 years
- CMT 1A patients with symptomatology defined as muscle weakness in at least foot dorsiflexion
Exclusion Criteria:
Due to possible influence on severity of the neuropathy:
- Known other disease that may cause a neuropathy, that may decrease mobility, or that may lead to severe disability or death in a short time
- Medication that may cause a neuropathy
- Chronic alcohol abuse
Due to study medication (ascorbic acid):
- Regular use of vitamin C
- Clinical or echographic signs of nephrolithiasis
- Reduced glomerular filtration rate
- Iron overload
- No regular dental control at the dentist
- Pregnancy or active pregnancy wish for women
Due to study design and primary outcome:
- Not signing the informed consent
- Psychiatric co-morbidity which may influence compliance
- Not being comfortable during nerve conduction studies of the median nerve
- A too small CMAP amplitude of the abductor pollicis brevis muscle for a proper determination of the nerve conduction velocity of the median nerve
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: 2
Placebo
|
Placebo 4 capsules b.i.d.
during 1 year
|
Experimental: 1
Ascorbic acid
|
Ascorbic acid 1000 mg (4 capsules of 250 mg) b.i.d.
during 1 year
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in motor nerve conduction velocity of the median nerve after 1 year
Time Frame: 1 year
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in minimal F response latency of the median nerve after 1 year
Time Frame: 1 year
|
1 year
|
Changes in compound muscle action potential amplitude and area after 1 year
Time Frame: 1 year
|
1 year
|
Change in motor unit number estimation of the abductor pollicis brevis muscle after 1 year
Time Frame: 1 year
|
1 year
|
Changes in handgrip strength, strength of armflexors, foot dorsiflexors, knee extensors and hip flexors after 1 year
Time Frame: 1 year
|
1 year
|
Change in overall disability sum score after 1 year
Time Frame: 1 year
|
1 year
|
Change in AMC Linear Disability Scale score after 1 year
Time Frame: 1 year
|
1 year
|
Evaluation of serum ascorbic acid concentrations during 1 year
Time Frame: 1 year
|
1 year
|
Evaluation of side effects during 1 year
Time Frame: 1 year
|
1 year
|
Collaborators and Investigators
Investigators
- Principal Investigator: C. Verhamme, MD, Department of Neurology, Academic Medical Center, University of Amsterdam
- Principal Investigator: M. Vermeulen, MD, PhD, Department of Neurology, Academic Medical Center, University of Amsterdam
- Principal Investigator: F. Baas, MD, PhD, Department of Neurology, Academic Medical Center, University of Amsterdam
- Principal Investigator: R. de Haan, MD, PhD, Department of Neurology, Academic Medical Center, University of Amsterdam
- Principal Investigator: M. de Visser, MD, PhD, Department of Neurology, Academic Medical Center, University of Amsterdam
- Principal Investigator: I. N van Schaik, MD, PhD, Department of Neurology, Academic Medical Center, University of Amsterdam
Publications and helpful links
General Publications
- Passage E, Norreel JC, Noack-Fraissignes P, Sanguedolce V, Pizant J, Thirion X, Robaglia-Schlupp A, Pellissier JF, Fontes M. Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease. Nat Med. 2004 Apr;10(4):396-401. doi: 10.1038/nm1023. Epub 2004 Mar 21.
- Verhamme C, van Schaik IN, Koelman JH, de Haan RJ, Vermeulen M, de Visser M. Clinical disease severity and axonal dysfunction in hereditary motor and sensory neuropathy Ia. J Neurol. 2004 Dec;251(12):1491-7. doi: 10.1007/s00415-004-0578-x.
- Verhamme C, de Haan RJ, Vermeulen M, Baas F, de Visser M, van Schaik IN. Oral high dose ascorbic acid treatment for one year in young CMT1A patients: a randomised, double-blind, placebo-controlled phase II trial. BMC Med. 2009 Nov 12;7:70. doi: 10.1186/1741-7015-7-70.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Nervous System Diseases
- Congenital Abnormalities
- Genetic Diseases, Inborn
- Neuromuscular Diseases
- Stomatognathic Diseases
- Neurodegenerative Diseases
- Peripheral Nervous System Diseases
- Heredodegenerative Disorders, Nervous System
- Nervous System Malformations
- Polyneuropathies
- Tooth Diseases
- Nerve Compression Syndromes
- Charcot-Marie-Tooth Disease
- Hereditary Sensory and Motor Neuropathy
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Protective Agents
- Micronutrients
- Vitamins
- Antioxidants
- Ascorbic Acid
Other Study ID Numbers
- 04/320
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Charcot-Marie-Tooth Disease
-
Hereditary Neuropathy FoundationRecruitingCharcot-Marie-Tooth Disease | Charcot-Marie-Tooth Disease, Type IA | Charcot-Marie-Tooth Disease Type 2A | Charcot-Marie-Tooth | Charcot-Marie-Tooth Disease, Type IB | Charcot-Marie-Tooth Disease Type 2 | Charcot-Marie-Tooth Disease, Type 2C | Charcot-Marie-Tooth Disease Type 2A2B | Charcot-Marie-Tooth... and other conditionsUnited States
-
University College, LondonUniversity of IowaUnknownCharcot-Marie-Tooth Disease, Type IA | Charcot-Marie-Tooth Disease Type 2A | Charcot-Marie-Tooth Disease, Type IB | Charcot-Marie-Tooth Disease, Type XUnited Kingdom
-
University Hospital, Clermont-FerrandCompletedCharcot-Marie-Tooth Type 1A NeuropathyFrance
-
University Hospital, Clermont-FerrandActive, not recruitingCharcot-Marie-Tooth Type 1A NeuropathyFrance
-
Pharnext S.C.A.Premier Research Group plc; Eurofins Optimed; Synteract HCR (Syneos Health); Gr... and other collaboratorsActive, not recruitingCharcot-Marie-Tooth Disease, Type IAUnited States, Belgium, Canada, France, Netherlands, Spain, United Kingdom
-
Samsung Medical CenterNot yet recruitingCharcot-Marie-Tooth Disease, Type 1
-
University of IowaJohns Hopkins University; University of Colorado, Denver; King's College Hospital... and other collaboratorsRecruitingCharcot-Marie-Tooth Disease, Type Ia (Disorder) | HMSNUnited States, Italy, United Kingdom, Australia
-
Tasly GeneNet Pharmaceuticals Co., LtdRecruitingCharcot-Marie-Tooth Type 1AChina
-
Nationwide Children's HospitalSuspendedCharcot-Marie-Tooth Neuropathy Type 1AUnited States
-
University of IowaChildren's Hospital of Philadelphia; University College London Hospitals; National... and other collaboratorsRecruitingCharcot Marie Tooth DiseaseUnited States, United Kingdom, Australia, Italy
Clinical Trials on ascorbic acid
-
Harokopio UniversityCompletedSymptomatic Knee OsteoarthritisGreece
-
Situs Cancer Research CenterSuspendedSarcoma | Adenocarcinoma | Carcinoma | Multiple Myeloma | Desmoplastic Small Round Cell TumorUnited States
-
DongGuk UniversityKorean Association For Vitamin ResearchCompleted
-
National Taiwan University Hospital Hsin-Chu BranchCompletedHemodialysis Access Failure
-
Sisli Hamidiye Etfal Training and Research HospitalCompletedCovid19 | Respiratory Distress Syndrome, AdultTurkey
-
Swiss Federal Institute of TechnologyCompletedIron-deficiency | Iron Deficiency AnemiaSwitzerland
-
Bangabandhu Sheikh Mujib Medical University, Dhaka...Unknown
-
Jewish General HospitalCompleted
-
Cairo UniversityCompletedPalatally Impacted CaninesEgypt